OC
INSY

Oppenheimer & Co’s Insys Therapeutics, Inc. INSY Stock Holding History

Oppenheimer & Co’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-6,001
Closed -$216K – 1508
2015
Q2 		$216K Buy
+6,001
New +$187K 0.01% 1259
2014
Q3 		– Sell
-19,624
Closed -$307K – 1523
2014
Q2 		$307K Buy
19,624
+564
+3% +$9.12K 0.01% 1042
2014
Q1 		$395K Buy
19,060
+2,560
+16% +$50.8K 0.01% 919
2013
Q4 		$213K Buy
+16,500
New +$229K 0.01% 1185

Other funds holding INSY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Oppenheimer & Co's INSY Position: Q3 2015 in Review

Oppenheimer & Co sold out of Insys Therapeutics, Inc. (INSY) in Q3 2015, closing a stake of 6,001 shares — an estimated $216K sold.

Oppenheimer & Co first reported a position in INSY in Q4 2013 and held it in 4 quarters. The position peaked at $395K in Q1 2014. 145 funds tracked by Wall St. Rank hold INSY as of Q3 2015.

  • Oppenheimer & Co reported no remaining Insys Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
  • Oppenheimer & Co sold 6,001 Insys Therapeutics, Inc. shares in Q3 2015, an estimated $216K.
  • Oppenheimer & Co first reported a position in Insys Therapeutics, Inc. in Q4 2013 and held it in 4 quarters.
  • Oppenheimer & Co's Insys Therapeutics, Inc. position peaked at $395K in Q1 2014.
  • 145 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q3 2015.

Based on Oppenheimer & Co's 13F filing for Q3 2015, filed 13 Nov 2015.